Soleno Therapeutics (SLNO) Cash from Operations (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Cash from Operations data on file, last reported at 25980000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 25980000.0, up 179.32% year-over-year; the trailing twelve-month figure through Mar 2026 was 105530000.0 (up 218.15% YoY), and the FY2025 annual result was 46798000.0, up 167.73% from the prior year.
• Cash from Operations eased to 25980000.0 in Q1 2026 per SLNO's latest filing, from 48704000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 48704000.0 in Q4 2025 and troughed at 32752000.0 in Q1 2025.
• A 5-year average of 2472882.35 and a median of 6332000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations sank 279.97% in 2024, then jumped 391.4% in 2025.
• A 5-year view of Cash from Operations shows it stood at 5143000.0 in 2022, then slipped by 22.77% to 6314000.0 in 2023, then slumped by 279.97% to 23991000.0 in 2024, then jumped by 303.01% to 48704000.0 in 2025, then plunged by 46.66% to 25980000.0 in 2026.
• Business Quant data shows SLNO's Cash from Operations at 25980000.0 in Q1 2026, 48704000.0 in Q4 2025, and 43494000.0 in Q3 2025.